

# Brief Education to Promote Maternal Influenza Vaccine Uptake: A Randomized Controlled Trial

---

WONG Wing Yu, Valerie<sup>a</sup>  
FONG Yee Tak, Daniel<sup>a</sup>  
LOK Yuet Wan, Kris<sup>a</sup>  
WONG Yuen Ha, Janet<sup>a</sup>  
SING Chu<sup>b</sup>  
CHOI Yin-yin, Alice<sup>c</sup>  
YUEN Yuet Sheung, Carol<sup>a</sup>  
Marie TARRANT,<sup>a§</sup>

<sup>a</sup>School of Nursing, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong

<sup>b</sup>Dept. of Obstetrics and Gynaecology, Kwong Wah Hospital, 25 Waterloo Road, Kowloon, Hong Kong

<sup>c</sup>Dept. of Obstetrics and Gynaecology, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong

## **§Corresponding Author Contact Information:**

Marie Tarrant  
Associate Professor, School of Nursing  
4/F, William M. W. Mong Block  
Li Ka Shing Faculty of Medicine  
21 Sassoon Road, Hong Kong  
Tel: +852 3917 6643  
Fax: +852 2872 6079  
Email: tarrantm@hku.hk

## Co-author Email Addresses:

VW: valywong@gmail.com  
DF: dytfong@hku.hk  
KL: krislok@hku.hk  
JW: janetyh@hku.hk  
SC: singc@ha.org.hk  
AC: choiyy@ha.org.hk  
CY: carol\_iou@hotmail.com

Word Count: 3530 words

Clinical Trial Registration: [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT01772901).

## 1 **1. Introduction**

2 Pregnant women have higher rates of influenza-related hospitalizations [1], complications [2,  
3 3], and mortality [2, 4] during pandemic and non-pandemic years. Influenza vaccination is  
4 beneficial and safe for pregnant women throughout pregnancy [5-8] and provides protection  
5 for the newborn in the first 6 months of life [9]. Although the World Health Organization  
6 (WHO) has identified pregnant women as having highest priority for seasonal influenza  
7 vaccination [10], maternal influenza vaccination rates are often lower than in other high-risk  
8 groups and the general population [11-13]. A recent review of influenza vaccination rates in  
9 pregnant women across 11 countries found vaccination rates ranged from 1.7%–88%, but  
10 were most often less than 50% [14].

11 Pregnant women who have more knowledge about the potential complications of  
12 influenza and the safety of the influenza vaccine are more likely to be vaccinated [15-17]. To  
13 date, the majority of interventions aimed at improving maternal influenza vaccination rates  
14 have targeted healthcare providers, primarily obstetricians, and encouraged them to discuss  
15 influenza vaccination with pregnant women [18-22]. Among pregnant woman-focused  
16 interventions, one trial showed that an education pamphlet, with or without a verbalized  
17 benefits statement, increased vaccination rates [23]. In other studies, one found that 5 weekly  
18 text messages to pregnant women about the importance of maternal influenza vaccination  
19 significantly increased vaccine uptake [24] while another found that 12 weekly text messages  
20 had no effect on maternal vaccination rates [25]. Chamberlain et al. [26] found that a multi-  
21 component vaccination promotion intervention consisting of provider to patient education,  
22 educational brochures, and an electronic patient-centred tutorial did not improve vaccine  
23 uptake. Frew et al. [27] evaluated the effect of two types of vaccination messages (i.e.,  
24 information about the benefits of vaccination vs. information about the risks of not  
25 vaccinating) and found that neither of the two message types significantly improved  
26 vaccination uptake.

27           The low rate of vaccine uptake in this target group and the conflicting evidence from  
28 evaluated interventions indicate a need to further develop interventions to improve maternal  
29 influenza vaccine rates. Although the Hong Kong government has endorsed the WHO  
30 recommendation for prioritizing pregnant women in seasonal and pandemic influenza  
31 vaccination programs, there is no free or subsidized vaccination program for this target group  
32 and publicly-funded antenatal clinics do not provide influenza vaccination as part of routine  
33 care to pregnant women. Pregnant women must get vaccinated in private clinics, primarily  
34 general practice clinics dispersed throughout the city. In public antenatal clinics, pregnant  
35 women do not have a dedicated provider and at each visit are assessed by a midwife or  
36 physician, depending on their stage of pregnancy and any complicating conditions. Thus,  
37 provider-focused interventions would likely be ineffective in such settings and interventions  
38 targeting pregnant women may be more appropriate to improve influenza vaccination  
39 coverage. The objective of the present study was to assess the effect of a brief education  
40 intervention targeting pregnant women on the uptake of influenza vaccination.

41

## 42 **2. Materials and Methods**

### 43 *2.1 Design, setting, and participants*

44 We designed a randomized controlled trial to evaluate the efficacy of a brief, one-to-one  
45 education session on the influenza vaccination rate during pregnancy and the proportion of  
46 participants seeking out influenza vaccination. A more detailed study protocol is reported  
47 elsewhere [28]. During two consecutive influenza seasons (2013-14 and 2014-15), pregnant  
48 women attending the antenatal clinics at four geographically-dispersed public hospitals in  
49 Hong Kong were screened for eligibility and recruited into the study by a research nurse.  
50 These hospitals were selected based on geographical representativeness and the large  
51 populations of eligible pregnant women from a wide range of socioeconomic backgrounds  
52 they served. Hong Kong has eight public and ten private hospitals that offer obstetric services.

53 Public health care, including high-quality antenatal, postnatal and well-child health care, is  
54 available free of charge to all Hong Kong residents. Private health care is available on a fee  
55 for service basis. In 2011, two-thirds of all Hong Kong women gave birth in public hospitals  
56 [29]. Although women giving birth in private hospitals are usually of higher socioeconomic  
57 status, many high-income families chose to access public maternity services because it is free,  
58 high quality and comprehensive.

59 Inclusion criteria were pregnant women: (a) with a singleton pregnancy; (b) at least 18  
60 years of age; (c) in at least the second trimester of pregnancy; (d) who spoke Cantonese; (e)  
61 were Hong Kong residents; (f) without serious medical conditions (i.e., cancers, rheumatoid  
62 arthritis, major psychiatric illnesses) or obstetrical complications (i.e., full placenta previa or  
63 diagnosed birth defects); (g) who had not yet received the influenza vaccination during this  
64 pregnancy; and (h) who would be staying in Hong Kong for at least 2 weeks after birth. Non-  
65 residents who are not entitled to health benefits in Hong Kong were excluded. Although  
66 influenza vaccine is safe in any trimester of pregnancy, we recruited pregnant women after  
67 the first trimester to avoid any perceived association between vaccination and early pregnancy  
68 complications.

69

## 70 2.2 Randomization and concealment

71 Participating pregnant women were randomized into either a standard care group or an  
72 intervention group at a 1:1 ratio, using block randomization with random block sizes of 2–8.  
73 An independent researcher who did not participate in the study generated an allocation  
74 sequence using Stata 13.1 statistical software (StataCorp 2013, *Stata Statistical Software:  
75 Release 13*, College Station, TX; StataCorp LP). Treatment assignments were placed in  
76 sequentially numbered, sealed, opaque envelopes. The research nurse selected the next  
77 envelope in the sequence to determine treatment allocation, after the eligible pregnant women

78 were given information about the study and had signed a written consent form. Blinding of  
79 the research nurse and participants was not possible given the nature of the intervention.

80

### 81 *2.3 Intervention*

82 Standard antenatal care consists of routine checking of maternal and fetal health by either  
83 obstetricians or midwives, along with health education to promote a healthy pregnancy.

84 **Childbirth preparation classes were available to all women attending the clinics for no**

85 **additional cost.** Recommendations and education about influenza vaccination in pregnancy

86 are not normally included in routine antenatal care. However, participants allocated to the

87 standard care group were provided with an education pamphlet on influenza vaccination in

88 pregnancy, developed by the Hong Kong Centre for Health Protection (CHP) [30] and freely

89 available in the antenatal clinics during the study.

90 The intervention group received standard care plus brief one-to-one education lasting

91 10 minutes that focused on four key recommendations identified from the literature: (i)

92 informing the participants about vaccination recommendations; (ii) encouraging them to

93 discuss vaccination with their **antenatal care provider or general practitioner (GP)**; (iii)

94 increasing accessibility of the vaccine by referral to clinics where vaccination could be

95 obtained; and (iv) providing **influenza-related** information from the official government

96 website and the website uniform resource locator [14]. Specifically, participants in the

97 intervention group were informed about: (i) the WHO [10] and Hong Kong CHP

98 recommendations [31] regarding influenza vaccine during pregnancy; (ii) potential

99 complications associated with influenza infection during pregnancy and for young infants;

100 (iii) the safety of influenza vaccination for pregnant women; (iv) potential benefits of

101 influenza vaccination for pregnant women and infants; and (v) where and how to get the

102 influenza vaccination in Hong Kong. **Almost all participants had a personal GP who provided**

103 influenza vaccine and for the few that did not, we provided information on nearby clinics that  
104 could provide vaccination.

105 Immediately after randomization, the intervention was delivered in a private room in  
106 the antenatal clinics so that participants in the standard care group were unable to overhear the  
107 education intervention and to ensure that all participants were unaware of the intervention  
108 other participants received. A digital flip chart was used to present the education content and  
109 participants were encouraged to express concerns and ask questions. To ensure consistency of  
110 intervention delivery, one research nurse carried out the education intervention across the four  
111 sites.

112

#### 113 2.4 Data collection

114 All participants completed a standard baseline questionnaire collecting: (i) key background  
115 data (i.e., age, marital status, education level, family income, and employment status); (ii)  
116 maternal health status (i.e., pre-existing health conditions, pregnancy-related health problems,  
117 gravidity and parity, and expected date of confinement); and (iii) influenza and influenza  
118 vaccine knowledge. Participants were subsequently followed up by telephone at 2–3 weeks  
119 after their expected delivery date by a study research assistant who had not been involved in  
120 participant recruitment and was blinded to participants' treatment allocation. During the  
121 follow-up telephone interviews, participants reported their influenza vaccination status during  
122 the pregnancy, reasons for receiving or not receiving influenza vaccination, discussion of  
123 influenza vaccination with antenatal care providers or GPs, attempts to receive the  
124 vaccination (i.e., participant went to their GP and requested the vaccine but were unable to  
125 receive it), and anti-vaccination advice from any healthcare professional.

126

127 *2.5 Outcome measures*

128 The primary study outcome was the self-reported influenza vaccination rate during pregnancy.  
129 The secondary outcomes were the proportion of participants who initiated discussion about  
130 influenza vaccination with a healthcare professional and the proportion of participants who  
131 attempted to get vaccinated.

132

133 *2.6 Sample size calculation*

134 Previous Hong Kong studies showed that seasonal influenza vaccination uptake among  
135 pregnant women ranged from 1.7%–5% [15, 32, 33]. Other studies also showed that in  
136 pregnant woman-focused interventions, the risk difference of influenza vaccination uptake  
137 among pregnant women before and after implementing the intervention ranged from 2% to  
138 39% [23-25, 27]. Therefore, an estimate of the “normal” influenza vaccination uptake rate  
139 among pregnant women in Hong Kong would be 5.0%, and an increase to 20% would be  
140 conservative but clinically meaningful. With a power of 0.80 and significance level of 0.05  
141 and using a chi-square test in the G-power statistical analysis program [34], we calculated that  
142 76 participants would be required for each group (152 participants in total). After accounting  
143 for a loss to follow-up and dropout rate of around 20%, approximately 92 participants per  
144 group were required, giving a total of 184 participants.

145

146 *2.7 Data analysis*

147 Baseline sociodemographic characteristics of the two groups were compared using a  $\chi^2$  test or  
148 a Fisher’s Exact Test for categorical variables and Student’s t-test for continuous variables.  
149 The proportion of participants in the two study groups who received influenza vaccination  
150 during pregnancy was compared using  $\chi^2$  tests. We further computed the odds ratios of  
151 vaccination using logistic regression, while adjusting for one baseline variable that was  
152 significantly different between the two groups. The intention-to-treat principle was used, with

153 missing values taken as no vaccination while the per-protocol analysis, with missing values  
154 removed, was reported as a comparison. We used  $\chi^2$  tests to compare the proportion of  
155 participants in the two groups who discussed influenza vaccination with a healthcare  
156 professional and the proportion of participants who attempted to receive influenza vaccination.  
157 Each estimate was accompanied by a 95% confidence interval (CI); a 5% level of significance  
158 was considered statistically significant in all statistical tests. Data analyses were performed  
159 using Stata statistical software (StataCorp 2015, *Stata Statistical Software: Release 14.1*,  
160 College Station, TX; StataCorp LP) [35].

161

## 162 *2.8 Ethical approval*

163 Ethical approval for the study was obtained from: (1) the Institutional Review Board of the  
164 University of Hong Kong/ Hospital Authority Hong Kong West Cluster; (2) the Kowloon  
165 West Cluster Research Ethics Committee (KWC-REC); and (3) the Ethics Committee of  
166 Hong Kong East Cluster (EC-HKEC). Informed written consent was obtained from all study  
167 participants before any personal data were collected and the intervention delivered. The  
168 research nurse informed each eligible pregnant woman about the purpose and nature of the  
169 study, the potential benefits and risks of participation, and their right to refuse to participate or  
170 withdraw at any time during the study without affecting the antenatal care they received.

171

## 172 **3. Results**

173 Data were collected from October 7, 2013, to February 4, 2014 (Year 1), and from October 20,  
174 2014, to December 23, 2014 (Year 2) (Figure 1). Data collection was interrupted in the first  
175 year when several cases of H7N9 avian influenza were admitted to Hong Kong public  
176 hospitals. Because of the raised influenza threat level, non-essential clinical duties were  
177 suspended in all public hospitals from December 7, 2013, through January 19, 2014.



178 Therefore, to achieve the required sample size, recruitment was resumed in the next influenza  
179 season. In total, 489 pregnant women were assessed for eligibility across all sites (Figure 1).  
180 Of these, 6% (n=29) did not meet the eligibility criteria, and 29% (n=140) declined to  
181 participate. Of the 321 who consented to participate, 160 were randomized to the standard  
182 care group and 161 to the intervention group; 305 (95%) participants completed follow-up.  
183 Nine participants were lost to follow-up, and seven were contacted but refused to complete  
184 follow-up. The treatment fidelity rate was 100%, because the intervention was delivered  
185 immediately after randomization.

186 An overview of participants' characteristics is presented in Table 1. The two groups  
187 were similar, except for a significantly higher proportion of participants with a pre-existing  
188 chronic illness in the intervention group (p=0.006). The reported pre-existing chronic illnesses  
189 were Hepatitis B carrier status (n=14), respiratory disease (n=6), thyroid disease (n=6), and  
190 others (n=13). The influenza vaccination rate for all participants was 15.6% (n=50) with a  
191 higher proportion of vaccinated participants in the intervention group (21.1%, n=34) than the  
192 standard care group (10%, n=16) (risk difference [RD] 11.1; 95% CI 3.3–19.0; p=0.006) (see  
193 Table 2). The number needed to treat was 9 (95% CI 5.3–30.4). After excluding those lost to  
194 follow-up, 22.5% (n=34) of participants in the intervention group received vaccination  
195 compared with 10.4% (n=16) in the standard care group (RD 12.1%; 95% CI 3.9–20.3;  
196 p=0.004). The logistic regression analysis showed that after adjusting for pre-existing chronic  
197 disease status, the intervention group was still significantly more likely to be vaccinated in the  
198 intention-to-treat analysis (odds ratio [OR] 2.45; 95% CI 1.28–4.68; p=0.007) and the per-  
199 protocol analysis (OR 2.52; 95% CI 1.32–4.82; p=0.005). There were no substantive  
200 differences in the vaccination uptake rates of participants between the two study years (see  
201 Supplementary Table).

202 The proportion of participants who initiated discussion about influenza vaccination  
203 with a healthcare professional was higher among participants in the intervention group

204 (19.9%; n=32) than in the standard care group (13.1%; n=21), but the difference was not  
205 statistically significant (p=0.10). Of participants who did not receive influenza vaccination  
206 during pregnancy (n=271), 45 reported that they had attempted to get vaccinated. A  
207 significantly higher proportion of participants who attempted to get vaccinated were in the  
208 intervention group (82.2%; n=37) than in the standard care group (17.8%; n=8) (p<0.001). If  
209 participants who made the attempt had received the vaccination, the vaccination rate would  
210 have been 44.1% (n=71) in the intervention group and 15% (n=24) in the standard care group  
211 (RD 29.1%, 95% CI 19.6%–38.6%, p<0.001) (Table 3). At baseline, only 6.2% (n=20) of  
212 participants reported that a healthcare professional had discussed influenza vaccination with  
213 them. At follow-up, 8.5% (n=26) of participants reported that they were advised against  
214 influenza vaccine by a healthcare professional, which included obstetricians (n=11), general  
215 practitioners (n=8), and nurses (n=7).

216

## 217 **4.0 Discussion**

218 The results of this study show that a brief, one-to-one education intervention for pregnant  
219 women significantly increased maternal influenza vaccination. However, the vaccination rate  
220 in the intervention group (21.1%) was still substantially below the Healthy People 2020 target  
221 vaccination rate of 80% [36]. This may be because other supportive vaccination practices (e.g.,  
222 on-site vaccine availability and positive recommendations from their obstetric healthcare  
223 provider) were not in place. Pregnant women needed to obtain the vaccination from a private  
224 provider, which increased vaccination barriers. In obstetric settings where vaccination is  
225 readily available however, the effectiveness of brief education may be greater as the barriers  
226 that exist in our setting would be removed. Furthermore, when our participants did attempt to  
227 get vaccinated, many were advised against vaccination by a healthcare professional or were  
228 unable to receive the vaccine. If these participants had received vaccination, the vaccination  
229 rate in the intervention group would have been approximately twice as high.

230 The relationship between healthcare professionals, pregnant women and influenza  
231 vaccination is complex. Studies show that doctors and nurses frequently recommend  
232 influenza vaccination to elderly or chronically ill clients or people perceived to be at highest  
233 risk from influenza morbidity and mortality [37-39]. However, healthcare professionals are  
234 less likely to recommend vaccination for young healthy populations [40-42]. Furthermore,  
235 rates of influenza vaccination among healthcare professionals, an identified risk group, are  
236 consistently low [43-45]. Studies of US obstetric healthcare providers have found that over  
237 85% report that they routinely recommend influenza vaccine to their pregnant patients [20, 46,  
238 47]. Other studies however, suggest that many obstetric healthcare providers are unaware of  
239 vaccine recommendations for pregnant women and even if aware, are reluctant to recommend  
240 vaccination [40, 42, 48, 49]. In addition, surveys of pregnant women have found that only 7–  
241 40% report receiving such a recommendation [32, 33, 50-52]. Although pregnant women who  
242 receive a vaccination recommendation from their healthcare provider are substantially more  
243 likely to receive influenza vaccination [14], only 30–70% of pregnant women receiving the  
244 recommendation get vaccinated [33, 50-52]. This suggests that even with knowledge of the  
245 benefits of vaccination, many pregnant women remain reluctant to get vaccinated. This  
246 reluctance is likely due to an long-held belief system that pregnant women should minimize  
247 exposing the fetus to any unknown or potentially adverse substances [46], especially those  
248 injected into the body. Evidence has shown that interventions targeting healthcare  
249 professionals improved maternal influenza vaccination rates [18, 21, 53]. In our study a nurse  
250 delivered the education intervention and recommended the vaccination to participants, and  
251 although vaccine uptake was significantly improved, rates were still suboptimal. Pregnant  
252 women may be more willing to follow recommendations from their regular GP or obstetric  
253 healthcare provider but some women may still be reticent to receive the vaccination during  
254 pregnancy [54]. In addition to maternal education, enthusiastic vaccination recommendations,

255 and on-site vaccine access, vaccine promotion through mass media and social media may help  
256 to further overcome these barriers [46].

257 In this study the vaccination coverage in the standard care group (~10%) was  
258 somewhat higher than in previous Hong Kong studies among pregnant women, where rates  
259 ranged from 1.7–6.2% [15, 32, 33]. The influenza vaccination pamphlet provided to  
260 participants in the standard care group was widely available in antenatal clinics. However, it  
261 is not given directly to pregnant women, and it is likely that few read the pamphlet. Therefore,  
262 it is possible that simply being given the influenza vaccination pamphlet by a nurse increased  
263 the women's risk perceptions and perceived importance of vaccination. Other studies have  
264 shown significant increases in maternal influenza vaccination coverage following the  
265 distribution of education pamphlets by **healthcare professionals** [23, 55]. In addition, pregnant  
266 women may perceive healthcare staff-delivered information as more personally relevant and  
267 important [56]. Although the effect may be small, actively distributing pamphlets is a simple  
268 action, easily implemented in clinical settings at a minimal cost.

269

#### 270 *4.1 Strengths and limitations*

271 This study provides high-quality evidence of the effectiveness of brief education in improving  
272 maternal influenza vaccination rates. First, random allocation and allocation concealment  
273 minimized treatment assignment bias. Second, there was a high participation rate. This might  
274 have been because the study involved only a brief onsite intervention, requiring less than 10  
275 minutes of participants' time, and a short follow-up telephone interview. Evidence shows that  
276 people are more likely to participate in studies with a low participation burden such as in-  
277 person or telephone interviews [57]. Third, as the intervention was delivered immediately  
278 after randomization, we achieved 100% treatment fidelity. Finally, the loss to follow-up rate  
279 was <5%, meaning the risk of attrition bias was minimal.

280 This study also has some limitations that need to be considered when interpreting the  
281 findings. First, participants were recruited from the antenatal clinics at four public hospitals;  
282 therefore, the demographic and socioeconomic characteristics might not be representative of  
283 all pregnant women in Hong Kong. When compared with the 2014 Hong Kong female  
284 population from 20-49 years of age, our sample had fewer participants in the lowest education  
285 category (7.2% vs. 17.9%) and more participants in the higher education category (42.4% vs.  
286 30.7%) [58]. Second, the higher-than-expected vaccination rate in the standard care group  
287 might indicate that study participants were more receptive to the influenza vaccination  
288 information than other pregnant women. As the study information sheet, the consent form,  
289 and the education pamphlet all identified that the study was on influenza vaccination, the  
290 standard care group may have also received some priming regarding the importance of  
291 influenza vaccine in pregnancy. Third, although we took measures to minimize potential  
292 contamination between the two treatment groups, we did not assess whether there was  
293 contamination or sharing of information between the participants. Fourth, the H7N9 avian  
294 influenza outbreak may also explain the higher-than-expected vaccination rate in the standard  
295 care group. However, outbreaks of avian influenza are not uncommon in Hong Kong [59] and  
296 these outbreaks have had minimal impact on influenza vaccination rates in various population  
297 and at risk groups [60, 61]. Fifth, it is also possible, as the assessment of the primary outcome  
298 relied on self-reported data, reporting or recall bias may have affected the study results. It was  
299 not possible to verify participants' vaccination status as most primary care providers work in  
300 solo practices that do not have centralized vaccination reporting systems. However, existing  
301 studies have shown that recall of vaccination status is accurate, and maternal recall is  
302 particularly reliable for pregnancy-related events [62-64]. In addition, the unavailability of  
303 influenza vaccine in the antenatal clinics may have limited the effect of antenatal education as  
304 other barriers such as employment or lack of childcare may have prevented pregnant women  
305 from being vaccinated. Finally, due to the nature of the intervention, participants and the

306 research nurse could not be blinded to the treatment allocation and this may have biased the  
307 study in some unmeasurable way.

308

#### 309 *4.2 Conclusion*

310 Although our study supports the effectiveness of brief education in improving maternal  
311 influenza vaccination rates, coverage remained low. It is possible that in populations with  
312 higher baseline vaccination rates, brief education may be sufficient to achieve target  
313 vaccination rates. However, in populations such as Hong Kong, where baseline vaccination  
314 rates are low, multi-component interventions are likely required. In addition to education  
315 about influenza vaccination, other supportive practices such as a direct healthcare professional  
316 recommendation, onsite vaccination, and promotion campaigns that specifically address  
317 maternal concerns and fears about vaccination may need to be implemented to reduce barriers  
318 and achieve optimal vaccination coverage.

319

320 Full text of the trial protocol is available at [www.biomedcentral.com/1471-2393/14/19](http://www.biomedcentral.com/1471-2393/14/19) [28].

321

#### 322 **Study Funding**

323 Funding for this study was provided by the Health and Medical Research Fund, Government  
324 of the Hong Kong Special Administration Region, Hong Kong SAR (Grant No. 12111272).

325

#### 326 **Conflict of Interest Statement**

327 The authors have no potential conflicts of interest to report.

328

#### 329 **Acknowledgement**

330 The authors thank Ms. Vincci Chan for her assistance with study management and telephone  
331 follow-up.

332 **Figure Caption**

333 Figure 1: Flow diagram of participants through each stage of the study

334

335 **References**

- 336 [1] Dodds L, McNeil SA, Fell DB, Allen VM, Coombs A, Scott J, et al. Impact of influenza  
337 exposure on rates of hospital admissions and physician visits because of respiratory  
338 illness among pregnant women. *CMAJ*. 2007;176:463-8.
- 339 [2] Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et  
340 al. H1N1 2009 influenza virus infection during pregnancy in the USA. *Lancet*.  
341 2009;374:451-8.
- 342 [3] Laibl VR, Sheffield JS. Influenza and pneumonia in pregnancy. *Clin Perinatol*.  
343 2005;32:727-38.
- 344 [4] Callaghan WM, Chu SY, Jamieson DJ. Deaths from seasonal influenza among pregnant  
345 women in the United States, 1998-2005. *Obstet Gynecol*. 2010;115:919-23.
- 346 [5] Pasternak B, Svanstrom H, Molgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et  
347 al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal  
348 death: cohort study in Denmark. *BMJ*. 2012;344:e2794.
- 349 [6] Baum U, Leino T, Gissler M, Kilpi T, Jokinen J. Perinatal survival and health after  
350 maternal influenza A(H1N1)pdm09 vaccination: A cohort study of pregnancies stratified  
351 by trimester of vaccination. *Vaccine*. 2015;33:4850-7.
- 352 [7] Fabiani M, Bella A, Rota MC, Clagnan E, Gallo T, D'Amato M, et al. A/H1N1 pandemic  
353 influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal  
354 outcomes in a cohort of pregnant women in Italy. *Vaccine*. 2015;33:2240-7.
- 355 [8] Steinhoff MC, Omer SB, Roy E, Arifeen SE, Raqib R, Dodd C, et al. Neonatal outcomes  
356 after influenza immunization during pregnancy: a randomized controlled trial. *CMAJ*.  
357 2012;184:645-53.
- 358 [9] Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of  
359 maternal influenza immunization in mothers and infants. *N Engl J Med*. 2008;359:1555-  
360 64.
- 361 [10] World Health Organization. Vaccines against influenza WHO position paper -  
362 November 2012. *Wkly Epidemiol Rec*. 2012;87:461-76.
- 363 [11] Bone A, Guthmann J-P, Nicolau J, Levy-Bruhl D. Population and risk group uptake of  
364 H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination  
365 campaign. *Vaccine*. 2010;28:8157-61.
- 366 [12] Mereckiene J, Cotter S, Nicoll A, Levy-Bruhl D, Ferro A, Tridente G, et al. National  
367 seasonal influenza vaccination survey in Europe, 2008. *Euro Surveill*. 2008;13:23.
- 368 [13] Sammon CJ, McGrogan A, Snowball J, de Vries CS. Pandemic influenza vaccination  
369 during pregnancy: an investigation of vaccine uptake during the 2009/10 pandemic  
370 vaccination campaign in Great Britain. *Hum Vaccin Immunother*. 2013;9:917-23.
- 371 [14] Yuen CY, Tarrant M. Determinants of uptake of influenza vaccination among  
372 pregnant women - A systematic review. *Vaccine*. 2014;32:4602-13.



- 373 [15] Tarrant M, Wu KM, Yuen CY, Cheung KL, Chan VH. Determinants of 2009 A/H1N1  
374 influenza vaccination among pregnant women in Hong Kong. *Matern Child Health J.*  
375 2013;17:23-32.
- 376 [16] Wilson RJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing  
377 vaccination acceptance during pregnancy globally: A literature review. *Vaccine.*  
378 2015;33:6420-9.
- 379 [17] Collins J, Alona I, Tooher R, Marshall H. Increased awareness and health care  
380 provider endorsement is required to encourage pregnant women to be vaccinated. *Hum*  
381 *Vaccin Immunother.* 2014;10:2922-9.
- 382 [18] Klatt TE, Hopp E. Effect of a best-practice alert on the rate of influenza vaccination  
383 of pregnant women. *Obstet Gynecol.* 2012;119:301-5.
- 384 [19] McCarthy EA, Pollock WE, Nolan T, Hay S, McDonald S. Improving influenza  
385 vaccination coverage in pregnancy in Melbourne 2010-2011. *Aust N Z J Obstet Gynaecol.*  
386 2012;52:334-41.
- 387 [20] Panda B, Stiller R, Panda A. Influenza vaccination during pregnancy and factors for  
388 lacking compliance with current CDC guidelines. *J Matern Fetal Neonatal Med.*  
389 2011;24:402-6.
- 390 [21] Sherman MJ, Raker CA, Phipps MG. Improving influenza vaccination rates in  
391 pregnant women. *J Reprod Med.* 2012;57:371-6.
- 392 [22] Wong VW, Lok KY, Tarrant M. Interventions to increase the uptake of seasonal  
393 influenza vaccination among pregnant women: A systematic review. *Vaccine.*  
394 2016;34:20-32.
- 395 [23] Meharry P, Cusson R, Stiller R, Vázquez M. Maternal influenza vaccination:  
396 Evaluation of a patient-centered pamphlet designed to increase uptake in pregnancy.  
397 *Matern Child Health J.* 2014;18:1205-14.
- 398 [24] Stockwell MS, Westhoff C, Kharbanda EO, Vargas CY, Camargo S, Vawdrey DK, et al.  
399 Influenza vaccine text message reminders for urban, low-income pregnant women: a  
400 randomized controlled trial. *Am J Public Health.* 2014;104 Suppl 1:e7-e12.
- 401 [25] Moniz MH, Hasley S, Meyn LA, Beigi RH. Improving influenza vaccination rates in  
402 pregnancy through text messaging: a randomized controlled trial. *Obstet Gynecol.*  
403 2013;121:734-40.
- 404 [26] Chamberlain AT, Seib K, Ault KA, Rosenberg ES, Frew PM, Cortes M, et al. Improving  
405 influenza and Tdap vaccination during pregnancy: A cluster-randomized trial of a multi-  
406 component antenatal vaccine promotion package in late influenza season. *Vaccine.*  
407 2015;33:3571-9.
- 408 [27] Frew PM, Saint-Victor DS, Owens LE, Omer SB. Socioecological and message framing  
409 factors influencing maternal influenza immunization among minority women. *Vaccine.*  
410 2014;32:1736-44.

- 411 [28] Wong VW, Fong DY, Tarrant M. Brief education to increase uptake of influenza  
412 vaccine among pregnant women: a study protocol for a randomized controlled trial.  
413 BMC Pregnancy Childbirth. 2014;14:19.
- 414 [29] Panel on Health Services. Latest arrangement for non-local pregnant women giving  
415 birth in Hong Kong. In: Food and Health Bureau, editor. Hong Kong 2012.
- 416 [30] Centre for Health Protection. Influenza vaccine safe and effective: A gift to your  
417 baby. Hong Kong: Author; 2013.
- 418 [31] Centre for Health Protection. Scientific Committee on Vaccine Preventable Diseases:  
419 recommendations on Seasonal Influenza Vaccination for the 2015/16 Season. In: Health  
420 Do, editor. Hong Kong: Department of Health; 2015.
- 421 [32] Lau JT, Cai Y, Tsui HY, Choi KC. Prevalence of influenza vaccination and associated  
422 factors among pregnant women in Hong Kong. Vaccine. 2010;28:5389-97.
- 423 [33] Yuen CYS, Fong DYT, Lee ILY, Sing C, Siu ES-m, Tarrant M. Prevalence and  
424 predictors of maternal seasonal influenza vaccination in Hong Kong. Vaccine.  
425 2013;31:5281-8.
- 426 [34] Faul F, Erdfelder E, Lang AG, Buchner A. G\*Power 3: a flexible statistical power  
427 analysis program for the social, behavioral, and biomedical sciences. Behav Res  
428 Methods. 2007;39:175-91.
- 429 [35] StataCorp. Stata Statistical Software: Release 14.1. College Station, Tx: StataCorp LP;  
430 2015.
- 431 [36] Healthy People 2020. Immunization and infectious diseases data details. Office of  
432 Disease Prevention and Health Promotion; 2016.
- 433 [37] de Souto Barreto P, Lapeyre-Mestre M, Vellas B, Rolland Y. Indicators of influenza  
434 and pneumococcal vaccination in French nursing home residents in 2011. Vaccine.  
435 2014;32:846-51.
- 436 [38] Ryu SY, Kim SH, Park HS, Park J. Influenza vaccination among adults 65 years or  
437 older: a 2009-2010 community health survey in the Honam region of Korea. Int J  
438 Environ Res Public Health. 2011;8:4197-206.
- 439 [39] Kroneman MW, van Essen GA. Variations in influenza vaccination coverage among  
440 the high-risk population in Sweden in 2003/4 and 2004/5: a population survey. BMC  
441 Public Health. 2007;7:113.
- 442 [40] Broughton DE, Beigi RH, Switzer GE, Raker CA, Anderson BL. Obstetric health care  
443 workers' attitudes and beliefs regarding influenza vaccination in pregnancy. Obstet  
444 Gynecol. 2009;114:981-7.
- 445 [41] Arriola CS, Mercado-Crespo MC, Rivera B, Serrano-Rodriguez R, Macklin N, Rivera  
446 A, et al. Reasons for low influenza vaccination coverage among adults in Puerto Rico,  
447 influenza season 2013-2014. Vaccine. 2015;33:3829-35.

- 448 [42] Mersereau P, Layton C, Smith L, Kendrick J, Mitchell E, Amoozegar J, et al. Prenatal  
449 care providers and influenza prevention and treatment: Lessons from the field. *Matern*  
450 *Child Health J.* 2012;16:479-85.
- 451 [43] Lu PJ, Ding H, Black CL. H1N1 and seasonal influenza vaccination of U.S. healthcare  
452 personnel, 2010. *Am J Prev Med.* 2012;43:282-92.
- 453 [44] Zhang J, While AE, Norman IJ. Nurses' vaccination against pandemic H1N1 influenza  
454 and their knowledge and other factors. *Vaccine.* 2012;30:4813-9.
- 455 [45] Vaux S, Noel D, Fonteneau L, Guthmann JP, Levy-Bruhl D. Influenza vaccination  
456 coverage of healthcare workers and residents and their determinants in nursing homes  
457 for elderly people in France: a cross-sectional survey. *BMC Public Health.* 2010;10:159.
- 458 [46] Arao RF, Rosenberg KD, McWeeney S, Hedberg K. Influenza vaccination of pregnant  
459 women: attitudes and behaviors of Oregon physician prenatal care providers. *Matern*  
460 *Child Health J.* 2015;19:783-9.
- 461 [47] Power ML, Leddy MA, Anderson BL, Gall SA, Gonik B, Schulkin J. Obstetrician-  
462 gynecologists' practices and perceived knowledge regarding immunization. *Am J Prev*  
463 *Med.* 2009;37:231-4.
- 464 [48] Maher L, Dawson A, Wiley K, Hope K, Torvaldsen S, Lawrence G, et al. Influenza  
465 vaccination during pregnancy: a qualitative study of the knowledge, attitudes, beliefs,  
466 and practices of general practitioners in Central and South-Western Sydney. *BMC family*  
467 *practice.* 2014;15:102.
- 468 [49] Tong A, Biringer A, Ofner-Agostini M, Upshur R, McGeer A. A cross-sectional study  
469 of maternity care providers' and women's knowledge, attitudes, and behaviours  
470 towards influenza vaccination during pregnancy. *J Obstet Gynaecol Can.* 2008;30:404-  
471 10.
- 472 [50] Blanchard-Rohner G, Meier S, Ryser J, Schaller D, Combescure C, Yudin MH, et al.  
473 Acceptability of maternal immunization against influenza: the critical role of  
474 obstetricians. *J Matern Fetal Neonatal Med.* 2012;25:1800-9.
- 475 [51] Maher L, Hope K, Torvaldsen S, Lawrence G, Dawson A, Wiley K, et al. Influenza  
476 vaccination during pregnancy: coverage rates and influencing factors in two urban  
477 districts in Sydney. *Vaccine.* 2013;31:5557-64.
- 478 [52] Wiley KE, Massey PD, Cooper SC, Wood NJ, Ho J, Quinn HE, et al. Uptake of influenza  
479 vaccine by pregnant women: a cross-sectional survey. *Med J Aust.* 2013;198:373-5.
- 480 [53] Mouzoon ME, Munoz FM, Greisinger AJ, Brehm BJ, Wehmanen OA, Smith FA, et al.  
481 Improving influenza immunization in pregnant women and healthcare workers. *Am J*  
482 *Manag Care.* 2010;16:209-16.
- 483 [54] Yuen CY, Dodgson JE, Tarrant M. Perceptions of Hong Kong Chinese women toward  
484 influenza vaccination during pregnancy. *Vaccine.* 2016;34:33-40.

- 485 [55] Yudin MH, Salaripour M, Sgro MD. Impact of patient education on knowledge of  
486 influenza and vaccine recommendations among pregnant women. *J Obstet Gynaecol Can.*  
487 2010;32:232-7.
- 488 [56] Petty RE, Cacioppo JT. *Attitudes and persuasion: classic and contemporary*  
489 *approaches*. Boulder, Colo.: Westview Press; 1996.
- 490 [57] Newington L, Metcalfe A. Factors influencing recruitment to research: qualitative  
491 study of the experiences and perceptions of research teams. *BMC Med Res Methodol.*  
492 2014;14:10.
- 493 [58] Census and Statistics Department. *Women and men in Hong Kong: key statistics.*  
494 2015 edition. Hong Kong: Hong Kong Census and Statistics Department; 2015.
- 495 [59] Parry J. Ten years of fighting bird flu. *Bull World Health Organ.* 2007;85:3-4.
- 496 [60] Yeung MP, Ng SK-C, Tong ETF, Chan SS-K, Coker R. Factors associated with uptake  
497 of influenza vaccine in people aged 50 to 64 years in Hong Kong: a case-control study.  
498 *BMC Public Health.* 2015;15:1-7.
- 499 [61] Mo PK, Lau JT. Influenza vaccination uptake and associated factors among elderly  
500 population in Hong Kong: the application of the Health Belief Model. *Health Educ Res.*  
501 2015;30:706-18.
- 502 [62] Bat-Erdene U, Metcalfe A, McDonald SW, Tough SC. Validation of Canadian mothers'  
503 recall of events in labour and delivery with electronic health records. *BMC Pregnancy*  
504 *Childbirth.* 2013;13 Suppl 1:S3.
- 505 [63] Liu J, Tuvblad C, Li L, Raine A, Baker LA. Medical record validation of maternal recall  
506 of pregnancy and birth events from a twin cohort. *Twin Res Hum Genet.* 2013;16:845-  
507 60.
- 508 [64] Cupul-Uicab LA, Gladen BC, Hernandez-Avila M, Longnecker MP. Reliability of  
509 reported breastfeeding duration among reproductive-aged women from Mexico. *Matern*  
510 *Child Nutr.* 2009;5:125-37.
- 511

**Table 1.** Baseline Characteristics of Participants by Intervention Group

Demographic variable	Standard care (n=160), No. (%)	Intervention (n=161), No. (%)	Total (n=321)	P
Maternal age, year M(SD)	33.8 ± 4.3	33.2 ± 4.0	33.5 ± 4.2	.21
Parity				
0	99 (61.9)	92 (57.1)	191 (59.5)	.69
1	53 (33.1)	60 (37.3)	113 (35.2)	
≥2	8 (5.0)	9 (5.6)	17 (5.3)	
Maternal education				
Compulsory secondary or below	12 (7.5)	11 (6.8)	23 (7.2)	.21
Upper secondary	64 (40.0)	68 (42.2)	53 (41.1)	
Some post-secondary	10 (6.3)	20 (12.4)	30 (9.4)	
University degree or above	74 (46.3)	62 (38.5)	136 (42.4)	
Place of birth				
Hong Kong SAR	116 (72.5)	112 (69.6)	228 (71.0)	.71
Mainland China	41 (25.6)	47 (29.2)	88 (27.4)	
Others	3 (1.9)	2 (1.2)	5 (1.6)	
Length of residency in Hong Kong				
<10 years	20 (12.5)	21 (13.0)	41 (12.8)	.75
10-15 years	26 (16.3)	31 (19.3)	57 (17.8)	
Since birth	114 (71.3)	109 (67.7)	223 (69.5)	
Family income <sup>1</sup>				
Below median	44 (27.5)	49 (30.4)	93 (29.0)	.56
Above median	116 (72.5)	112 (69.6)	228 (71.0)	
Smoked during pregnancy				
No	158 (98.8)	157 (97.5)	315 (98.1)	.69
Yes	2 (1.3)	4 (2.5)	6 (1.9)	
Pre-existing chronic illness				
No	149 (93.1)	134 (83.2)	283 (88.2)	.006
Yes	11 (6.9)	27 (16.8)	38 (11.8)	
Types: (some participants had >1 illness)				--
Hepatitis B carrier status	3 (27.3)	11 (40.7)	14 (36.8)	
Respiratory disease	1 (9.1)	5 (18.5)	6 (15.8)	
Thyroid disease	1 (9.1)	5 (18.5)	6 (15.8)	
Others	6 (54.5)	7 (25.9)	13 (34.2)	
Pregnancy related health problem				
No	125 (78.1)	126 (78.3)	251 (78.2)	.98
Yes	35 (21.9)	35 (21.7)	70 (21.8)	
Types: (some participants had >1 health problem)				--
Gestational diabetes	13 (37.1)	19 (54.3)	32 (45.7)	
Anaemia	15 (42.9)	13 (37.1)	28 (40.0)	
Hypertension	2 (5.7)	4 (11.4)	6 (8.6)	
Others	5 (14.3)	2 (5.7)	7 (10.0)	

<sup>1</sup>Median household income in HK in 2011 was \$20,000 to \$24,999 HKD per month (1USD=7.7HKD)

**Table 2.** Observed Influenza Vaccine Uptake During Pregnancy by Treatment Group<sup>1</sup>

	Treatment group, n (%)		RD, % (95% CI)	<i>P</i>
	Standard care	Intervention		
Intention-to-treat analysis <sup>2</sup>				
Vaccinated	16 (10.0)	34 (21.1)		
Non-vaccinated	144 (90.0)	127 (78.9)	11.1 (3.3–19.0)	0.006
Per-protocol analysis <sup>3</sup>				
Vaccinated	16 (10.4)	34 (22.5)		
Non-vaccinated	138 (89.6)	117 (77.5)	12.1 (3.9–20.3)	0.004

RD=Risk Difference; CI=Confidence Interval

<sup>1</sup>The actual influenza vaccine uptake rate among pregnant women<sup>2</sup>In the standard care group, n=160. In the intervention group, n=161.<sup>3</sup>In the standard care group, n=154. In the intervention group, n=151

**Table 3.** Expected Influenza Vaccine Uptake During Pregnancy by Treatment Groups<sup>1</sup>

	Treatment group, n (%)		RD, % (95% CI)	<i>P</i>
	Standard care	Intervention		
Intention-to-treat analysis <sup>2</sup>				
Vaccinated	24 (15.0)	71 (44.1)		
Non-vaccinated	136 (85.0)	90 (55.9)	29.1 (19.6–38.6)	<0.001
Per-protocol analysis <sup>3</sup>				
Vaccinated	24 (15.6)	71 (47.0)		
Non-vaccinated	130 (84.4)	80 (53.0)	31.4 (21.6–41.2)	<0.001

RD=Risk Difference; CI=Confidence Interval

<sup>1</sup>The estimated influenza vaccination rate if participants who attempted to be vaccinated had received the vaccine

<sup>2</sup>In the standard care group, n=160. In the intervention group, n=161.

<sup>3</sup>In the standard care group, n=154. In the intervention group, n=151

